InfuSystems Holdings Inc

Several biotech stocks reached 52-week highs on Tuesday, driven by second-quarter earnings reports and regulatory milestones. UFP Technologies surged over 25% to $338.70 after reporting net income of $20.9 million on a 15.1% sales increase to $174 million. InfuSystem Holdings climbed over 33% to $12.49 as second-quarter revenue rose 2.6% to $36.9 million, with Patient Services revenue up 15% offsetting a 16% decline in Device Solutions. SOPHiA Genetics gained over 20% to $6.98 following a 27% revenue jump to $23.3 million, fueled by 64% growth in the U.S. market. Replimune Group touched $13.86 intraday after a favorable advisory committee opinion on its RP1 BLA, though the FDA's August 2 response deadline passed without an update. Parabilis Medicines rose over 5% to $36.69, its highest since its June 11 IPO that raised $770.5 million.

InfuSystem Holdings reaffirmed its full-year outlook for pro forma annual revenue growth of 6% to 8% and an adjusted EBITDA margin in the low to mid-20% range, consistent with its longer-term target of 22% to 25%. The guidance adjusts for an expected $7.1 million reduction in annual revenue from the GE Healthcare biomedical services contract restructuring, which management said improves earnings by lowering direct contract expenses. Second-quarter revenue reached a quarterly record of $36.9 million, up 2.6% from the prior year, despite a $1.6 million headwind from the GE restructuring. Oncology revenue surpassed $20 million for the first time, while Wound Care net revenue grew by $2.1 million year-over-year, driven mainly by compression devices for lymphedema patients. Consolidated gross margin expanded to 58%, and net income rose to $3.2 million, or $0.15 per diluted share.